Merck to Participate at the Citi 2016 Global Healthcare Conference
Dateline City:
KENILWORTH, N.J.KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
announced today that Dr. Roger M. Perlmutter, president, Merck Research
Laboratories, is scheduled to participate at the Citi 2016 Global
Healthcare Conference in New York on Dec. 7, 2016 at 12:35 p.m. EST.
Investors, analysts, members of the media and the general public are
invited to listen to a live audio webcast of the presentation at http://investors.merck.com/investors/webcasts-and-presentations/default.aspx.Language:
EnglishContact: MerckM...
Source: Merck.com - Corporate News - December 6, 2016 Category: Pharmaceuticals Tags: Corporate News Financial News Latest News #Merck #MRK $MRK Citi MSD NYSE:MRK Source Type: news
FDA Grants Priority Review to Supplemental Biologics License Application (sBLA) for Merck ’s KEYTRUDA® (pembrolizumab) in Relapsed or Refractory Classical Hodgkin Lymphoma
Dateline City:
KENILWORTH, N.J.KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the U.S. Food and Drug Administration (FDA) has
accepted for review the supplemental Biologics License Application
(sBLA) for KEYTRUDA® (pembrolizumab), the company ’s anti-PD-1
therapy, for the treatment of patients with refractory classical Hodgkin
lymphoma (cHL) or for patients who have relapsed after three or more
prior lines of therapy.Language:
EnglishContact: MerckMedia:Pamela Eisele, 267-305-3558orKim Hamilton...
Source: Merck.com - Corporate News - December 1, 2016 Category: Pharmaceuticals Tags: Oncology Newsroom Prescription Medicine News Corporate News Latest News #Merck #MRK $MRK Keytruda MSD Source Type: news
Actress Bellamy Young, Merck, and Leading Lung Cancer Advocates Urge Those Impacted by Lung Cancer to Test. Talk. Take Action.
Dateline City:
KENILWORTH, N.J. Young to Help Educate on the Importance of Biomarker Testing in Non-Small Cell Lung CancerKENILWORTH, N.J.--(BUSINESS WIRE)--Acclaimed actress and singerBellamy Young lost her father to
lung cancer, and she is now sharing her personal experience as part ofTest.
Talk. Take Action., a new awareness campaign focused on increasing
people ’s understanding of biomarkers and the role they play in the
treatment of non-small cell lung cancer (NSCLC).Language:
EnglishContact: MediaMerckCourtney Ronaldo, 908-236-1108orChristiana Pascale, 212-257-6722Med...
Source: Merck.com - Corporate News - November 29, 2016 Category: Pharmaceuticals Tags: Oncology Newsroom Corporate News Latest News #Merck #MRK $MRK Lung Cancer MSD Source Type: news
FDA Grants Priority Review to Merck ’s Supplemental Biologics License Application (sBLA) Seeking Approval for KEYTRUDA® (pembrolizumab) for New Indication in Microsatellite Instability-High Cancer
Dateline City:
KENILWORTH, N.J.KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the U.S. Food and Drug Administration (FDA)
accepted for review the supplemental Biologics License Application
(sBLA) for KEYTRUDA® (pembrolizumab), the company ’s anti-PD-1
therapy, for the treatment of previously treated patients with advanced
microsatellite instability-high (MSI-H) cancer.Language:
EnglishContact: MerckMedia:Pamela Eisele, 267-305-3558orKim Hamilton, 908-740-1863orInvestors:Teri Loxam, 908-740-1986o...
Source: Merck.com - Corporate News - November 28, 2016 Category: Pharmaceuticals Tags: Oncology Newsroom Prescription Medicine News Corporate News Latest News #Merck #MRK $MRK Keytruda MSD Source Type: news
Merck Announces Increased Quarterly Dividend
Dateline City:
KENILWORTH, N.J.KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today announced that the Board of Directors has increased the company ’s
quarterly dividend to $0.47 per outstanding share of the company’s
common stock, up $0.01 from $0.46 per outstanding share paid last
quarter. Payment will be made on Jan. 9, 2017, to stockholders of record
at the close of business on Dec. 15, 2016.Language:
EnglishContact: MerckMedia:Lainie Keller, 908-236-5036orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898T...
Source: Merck.com - Corporate News - November 22, 2016 Category: Pharmaceuticals Tags: Corporate News Financial News #MRK $MRK Merck MSD Source Type: news
Merck Foundation Announces $10 Million Initiative to Improve Access to High-Quality Diabetes Care in Vulnerable and Underserved U.S. Communities
Dateline City:
KENILWORTH, N.J. Non-Profit Organizations Invited to Apply for Grants to Improve Access to Diabetes CareKENILWORTH, N.J.--(BUSINESS WIRE)--The Merck Foundation (Foundation) announced today the launch of a new
initiative,Bridging the Gap: Reducing Disparities in Diabetes Care
(Bridging the Gap),to improve access to high-quality diabetes care
and reduce health disparities for vulnerable and underserved populations
in the United States. With $10 million in funding from the Foundation
over five years,Bridging the Gap will build sustainable
partnerships across sectors to su...
Source: Merck.com - Corporate News - November 17, 2016 Category: Pharmaceuticals Tags: Corporate News Corporate Responsibility News Latest News #Merck #MRK $MRK Diabetes Merck Foundation MSD Source Type: news
Merck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection
Dateline City:
KENILWORTH, N.J. Phase 2 Data Presentations at The Liver Meeting® Detail SVR12 Rates from Two Studies as Well as SVR8 Rates in Patients for Whom Direct-Acting Antiviral Treatment Previously FailedKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada,
today announced the presentation of results from three Phase 2 clinical
trials evaluating MK-3682B (MK-3682/grazoprevir/ruzasvir1),
the company ’s investigational all-oral, triple-combination regimen for
the treatment of chronic hepatitis C (HCV) infection (informally
...
Source: Merck.com - Corporate News - November 13, 2016 Category: Pharmaceuticals Tags: Hepatitis C Newsroom Corporate News Latest News #Merck #MRK $MRK MSD Source Type: news
Merck Announces Presentation of New Findings for ZEPATIER ™ (Elbasvir and Grazoprevir) in Patients with Chronic Hepatitis C at The Liver Meeting®
Dateline City:
KENILWORTH, N.J.KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada,
today announced results from multiple analyses atThe
Liver Meeting® 2016, which provide additional evidence
supporting the use of ZEPATIER ™ (elbasvir and grazoprevir) 50mg/100mg
tablets in chronic hepatitis C virus (HCV) genotype (GT) 1- or
GT4-infected patient populations, including those who receive opioid
agonist therapy (OAT), are infected with chronic HCV GT1b, use proton
pump inhibitors (PPIs) or ha ve moderate kidney disease. (Source: Merc...
Source: Merck.com - Corporate News - November 12, 2016 Category: Pharmaceuticals Tags: Hepatitis C Newsroom Corporate News Latest News #Merck #MRK $MRK MSD The Liver Meeting ZEPATIER Source Type: news
Merck Prices EUR 1.0 Billion Debt Offering
Dateline City:
KENILWORTH, N.J.KENILWORTH, N.J.--(BUSINESS WIRE)--Merck& Co., Inc., (NYSE:MRK), known as MSD outside the United States
and Canada, priced today a EUR 1.0 billion public offering of two series
of Euro-denominated senior unsecured notes (collectively, the “New
Notes”). Based on Oct. 21, 2016, closing exchange rates the EUR 1.0
billion equates to approximately $1.087 billion. The notes include:
EUR 500 million of 0.500% notes due Nov. 2024EUR 500 million of
1.375% notes due Nov. 2036Language:
EnglishContact: Merck& Co., Inc.Media:Lainie Keller, 908-236-5036Trac...
Source: Merck.com - Corporate News - October 26, 2016 Category: Pharmaceuticals Tags: Corporate News Financial News Latest News #Merck #MRK $MRK MSD NYSE:MRK Source Type: news
Merck Highlights Ongoing Commitment to Fighting Infectious Diseases with More than 30 Data Presentations at ID Week 2016
Dateline City:
KENILWORTH, N.J.KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today announced that researchers will provide more than 30 scientific
data presentations on the company ’s established and investigational
infectious disease medicines and vaccines at ID Week 2016 in New Orleans
from Oct. 26-30.Language:
EnglishContact: MerckMedia:Pamela Eisele, 267-305-3558Robert Consalvo, 908-295-0928Skip Irvine, 215-652-6059orInvestors:Amy Klug, 908-740-1898Michael DeCarbo, 908-740-1807Ticker Slug:Ticker:MRKExchange:NYSErea...
Source: Merck.com - Corporate News - October 26, 2016 Category: Pharmaceuticals Tags: Corporate News Latest News #Merck #MRK $MRK Infectious Diseases MSD NYSE:MRK Source Type: news
Merck Announces Third-Quarter 2016 Financial Results
Dateline City:
KENILWORTH, N.J. Third-Quarter 2016 Worldwide Sales Were $10.5 Billion, an Increase of 5 Percent, Including a 1 Percent Negative Impact from Foreign Exchange Third-Quarter 2016 GAAP EPS Was $0.78; Third-Quarter Non-GAAP EPS Was $1.07 Company Updates EPS Guidance: Full-Year 2016 GAAP EPS to be Between $2.02 and $2.09; Full-Year 2016 Non-GAAP EPS to be Between $3.71 and $3.78 Advanced KEYTRUDA Development Program FDA Approved KEYTRUDA for Previously Untreated Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Have High PD-L1 Expr...
Source: Merck.com - Corporate News - October 25, 2016 Category: Pharmaceuticals Tags: Corporate News Financial News Latest News #Merck #MRK $MRK earnings MSD NYSE:MRK Source Type: news
FDA Approves Merck ’s ZINPLAVA™ (bezlotoxumab) to Reduce Recurrence of Clostridium difficile Infection (CDI) in Adult Patients Receiving Antibacterial Drug Treatment for CDI Who Are at High Risk of CDI Recurrence
Dateline City:
KENILWORTH, N.J.KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the U.S. Food and Drug Administration (FDA) has
approved ZINPLAVA ™ (bezlotoxumab) Injection 25 mg/mL. Merck anticipates
making ZINPLAVA available in first quarter 2017.Language:
EnglishContact: MerckMedia:Pamela Eisele, 267-305-3558orRobert Consalvo, 908-236-1127orInvestors:Teri Loxam, 908-740-1986orAmy Klug, 908-740-1898Ticker Slug:Ticker:MRKExchange:NYSEread more (Source: Merck.com - Corporate News)
Source: Merck.com - Corporate News - October 22, 2016 Category: Pharmaceuticals Tags: Corporate News Latest News #Merck #MRK $MRK CDI MSD ZINPLAVA Source Type: news
Merck Announces Pivotal Phase 3 Study of Letermovir, an Investigational Antiviral Medicine for Prevention of Cytomegalovirus (CMV) Infection in High-Risk Bone Marrow Transplant Patients, Met Primary Endpoint
Dateline City:
KENILWORTH, N.J.KENILWORTH, N.J.--(BUSINESS WIRE)--Merck& Co., Inc. (NYSE: MRK), known as MSD outside the United States
and Canada, today announced that the pivotal Phase 3 clinical study of
letermovir, an investigational antiviral medicine, met its primary
endpoint.Language:
EnglishContact: MerckMedia:Pam Eisele, 267-305-3558Robert Consalvo, 908-236-1127orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898Ticker Slug:Ticker:MRKExchange:NYSEread more (Source: Merck.com - Corporate News)
Source: Merck.com - Corporate News - October 19, 2016 Category: Pharmaceuticals Tags: Corporate News Latest News #Merck #MRK $MRK Letermovir MSD NYSE:MRK Source Type: news
Merck Research Laboratories Facilities Designated as “Milestones in Microbiology” Sites by the American Society for Microbiology
Dateline City:
KENILWORTH, N.J.KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
announced today that Merck Research Laboratories (MRL) facilities in
Rahway, N.J., and West Point, Pa., have been designated as “Milestones
in Microbiology” sites by the American Society for Microbiology (ASM)
for their contributions to anti-infectives and vaccines, respectively.
This is the first time a biopharmaceutical company has received this
recognition.Language:
EnglishContact: Media:Pam Eisele, 267-305-3558Ian McConnell, 908-740-192...
Source: Merck.com - Corporate News - October 17, 2016 Category: Pharmaceuticals Tags: Corporate News Latest News #Merck #MRK $MRK ASM MSD NYSE:MRK Source Type: news
Merck Launches Biosimilars Clarified, a New Online Educational Resource about Biosimilar Medicines for Patients and the Healthcare Community
Dateline City:
KENILWORTH, N.J.KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced the launch ofBiosimilars Clarified (www.merckclarifiesbiosimilars.com),
a new educational website for patients, caregivers and the healthcare
community that is designed to provide clear, concise and straightforward
information about biosimilar medicines.Language:
EnglishContact: MerckRobert Consalvo, 908-236-1127Ticker Slug:Ticker:MRKExchange:NYSEread more (Source: Merck.com - Corporate News)
Source: Merck.com - Corporate News - October 14, 2016 Category: Pharmaceuticals Tags: Corporate News Latest News #Merck #MRK $MRK biosimilar MSD NYSE:MRK Source Type: news
